Metformin Combined with Alendronate Ameliorates Osteoarthritis by Attenuating RANKL-Induced Bone Resorption and Protecting Cartilage Against Degradation

Yanjing Guo,Ruijia Yang,Sujing Zong,Zhenyu Wang,Jing Zhao,Chongwei Chen,Chunfang Wang,Shaowei Wang

DOI: https://doi.org/10.21203/rs.3.rs-1378528/v1

2022-01-01

Abstract:Background The purpose of the present study was to investigate the effect of metformin combined with alendronate on subchondral bone and cartilage degeneration in a destabilization of the medial meniscus (DMM)-induced osteoarthritis (OA) mouse model. Method The effect of metformin on OA was assessed by H&E, safranin O/fast green, immunohistochemical and tartrate-resistant acid phosphatase (TRAP) staining. The Osteoarthritis Research Society International (OARSI) criteria were used to grade the degeneration of articular cartilage. ATDC5 cells were stimulated with 10 ng/mL IL-1β to establish an in vitro model of OA. Bone marrow macrophages were isolated. Cell proliferation was examined using CCK-8 assays. Cartilage extracellular matrix degradation was analyzed using Alcian Blue staining and high-density culture. Osteoclastogenesis was analyzed using TRAP staining. The mitochondrial membrane potential of ATDC5 cells and osteoclasts was determined by JC-1 fluorescent staining. Immunostaining, RT–PCR, and western blot analyses were carried out to examine protein and RNA expression levels. Result There were lower OARSI scores and fewer TRAP-positive cells in DMM mice after treatment with metformin combined with alendronate. In cartilage, metformin inhibited the expression of MMP3 and MMP13 in IL-1β-stimulated OA chondrocytes and increased the expression of Sox9 and aggrecan. In parallel, metformin also inhibited cartilage matrix degradation, as shown by Alcian blue staining and SO/FG staining in ATDC5 cells and cartilage tissues. Moreover, metformin and alendronate downregulated the levels of specific genes and proteins (NFATc1, c-Fos, DC-STAMP, TNFRSF11, CTSK), thereby inhibiting osteoclast differentiation in vitro. Mechanistically, metformin increased the expression of phospho-AMPK alpha1, attenuated the phosphorylation of NF-κB, and reduced reactive oxygen species (ROS) levels. Conclusion Metformin combined with alendronate may be a useful candidate for attenuating early-stage OA. This would be an ideal drug/drug combination for treating osteoarthritis in the presence of osteoporosis combined with T2D.